Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Omics Analysis of Lung Adenocarcinoma with KRAS G12 Mutations

ABSTRACT: We conducted a proteomic analysis of LUAD patients with KRAS G12 mutations, and explore the interactome of KRAS G12 proteins. In conclusion, the findings of this study provide a deep understanding of the molecular mechanism of KRAS G12 mutation-driven LUAD.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Lung

SUBMITTER: Jiangli Lu

LAB HEAD: Xinyu Shi

PROVIDER: PXD058891 | Pride | 2026-06-08

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	A549_G12C_1.raw	Raw
	A549_G12C_2.raw	Raw
	A549_G12C_3.raw	Raw
	A549_G12D_1.raw	Raw
	A549_G12D_2.raw	Raw

Items per page:

1 - 5 of 127

Publications

Integrative proteomic characterization of human lung adenocarcinoma with KRAS G12 mutations reveals molecular pathogenesis.

Shi Xinyu X Hu Liling L Huang Yongshi Y Zhang Mei-Fang MF Ying Xingfeng X Yuan Xiaoyi X Wen Nengqiao N Lu Jiangli J Zou Hanchen H Tan Xiaohui X He Qing-Yu QY Wang Fang F Yang Hong H Zhang Chris Zhiyi CZ

Journal of advanced research 20250914

<h4>Introduction</h4>Integrated proteogenomic studies of lung adenocarcinoma (LUAD) have provided unique insights with potential clinical effects. Comprehensive proteomic analyses are needed to better understand the molecular landscape of LUAD with KRAS G12 mutations.<h4>Objectives</h4>This study aims to characterize the proteogenomic profile of LUAD with KRAS G12 mutation variants.<h4>Methods</h4>We performed next-generation sequencing (NGS) on 9,479 solid tumors, including 3,523 lung cancers. ...[more]

PMID: 40957478

Similar Datasets

Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma [scRNA-seq]

Project description:Lung adenocarcinoma (LUAD), commonly driven by KRAS mutations, is responsible for 7% of all cancer mortality. The first allele-specific KRAS inhibitors were recently approved in LUAD, but clinical benefit is limited by intrinsic and acquired resistance. LUAD predominantly arises from alveolar type 2 (AT2) cells, which function as facultative alveolar stem cells by self-renewing and replacing alveolar type 1 (AT1) cells. Using genetically engineered mouse models, patient-derived xenografts, and patient samples we found inhibition of KRAS promotes transition to a quiescent AT1-like cancer cell state in LUAD tumors. Similarly, suppressing Kras induced AT1 differentiation of wild-type AT2 cells upon lung injury. The AT1-like LUAD cells exhibited high growth and differentiation potential upon treatment cessation, whereas ablation of the AT1-like cells robustly improved treatment response to KRAS inhibitors. Our results uncover an unexpected role for KRAS in promoting intra-tumoral heterogeneity and suggest targeting alveolar differentiation may augment KRAS-targeted therapies in LUAD.

2023-11-01 | GSE246481 | GEO

Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma [RNA-seq]

2023-11-01 | GSE246480 | GEO

Targeted KRAS(G12V) degradation elicits efficient and durable lung adenocarcinoma regression in vivo

Project description:Recent drug discovery breakthroughs led to the approval of KRASG12C inhibitors in lung adenocarcinoma (LUAD). Unfortunately, clinical responses remain limited due to rapid resistance onset. Proteolysis-targeting chimeras (PROTACs) have emerged as promising alternatives to traditional inhibition. However, there is limited mechanistic understanding of KRAS degradation in vivo. Here, we developed a preclinical LUAD mouse model and demonstrated that targeted KRAS degradation induces rapid tumor regression. Transcriptional and histological analyses revealed a substantial remodeling of the tumor microenvironment. Notably, the low resistance rate observed during long-term treatment stems from proteolysis machinery dysregulation rather than KRAS absence adaptation, indicating resistance mechanisms distinct from KRAS inhibition. Our findings highlight the therapeutic potential of KRAS degradation in LUAD, offering insights into cell-intrinsic and extrinsic mechanisms driving durable antitumor responses and supporting further clinical exploration.

2026-05-13 | PXD058734 | Pride

Mapping the Interactome of KRAS and Its G12C/D/V Mutants by Integrating TurboID Proximity Labeling with Quantitative Proteomics

Project description:RAS is one of the most frequently mutated proto-oncogenes in human malignancies, with mutation sites and subtypes exhibiting tumor-type dependent distribution. Oncogenic RAS mutations will maintain continuously GTP-bound activation states that leading to dysregulation of downstream signaling, ultimately disrupting cellular homeostasis to induce malignant transformation of cells. In this study, we employed TurboID proximity-labeling technology integrated with quantitative proteomics LC-MS/MS to systematically characterize the proximal binding proteins of wild-type KRAS and three high-frequency oncogenic mutant subtypes G12C, G12D and G12V. Through comprehensive bioinformatic analysis of mutation-specific interaction networks and distinct metabolic pathways, we identified significant enrichment of mutant KRAS binding proteins in insulin signaling pathway, reactive oxygen species related pathways, glucose and lipid metabolism and so on. Metabolic reprogramming pathways in KRAS G12 mutations collectively fuel tumor proliferation and immune evasion. In addition, we also comparatively analyzed the proximal binding proteins similarity in three G12 mutants. Notably, we observed that the KRAS E3 ubiquitin ligase adaptor LZTR1 diminished binding with mutations, and the mTORC1 important regulatory protein LAMTOR1 was enhanced recruitment by mutations. This multi-dimensional profiling delineates a comprehensive mapping of KRAS WT and G12 mutant interactomes and unveils the metabolic reprogramming pathways associated with KRAS activating mutations. Our analysis result provides potential therapeutic targets for KRAS-driven tumorigenesis while establishing a mechanistic framework for developing KRAS mutation-specific therapeutic strategies.

2025-06-09 | PXD062101 | Pride

Subtype-specific heterogeneity of anti-epidermal growth factor receptor antibody sensitivity in KRAS-mutant colorectal cancer revealed by patient-derived organoids

Project description:Anti–epidermal growth factor receptor (anti-EGFR) antibodies are widely used in the treatment of colorectal cancer (CRC), and KRAS mutation status is commonly used as a predictive biomarker for therapeutic responsiveness. Nevertheless, emerging evidence suggests that drug sensitivity among KRAS-mutant CRC is heterogeneous and varies according to mutation subtype. In this study, we reevaluated the determinants of anti-EGFR antibody sensitivity using a patient-derived CRC organoid library. Eight organoid lines comprising KRAS wild-type, KRAS G12-mutant, and KRAS G13-mutant tumors were subjected to drug sensitivity assays. Although KRAS G12-mutant organoids generally exhibited reduced responsiveness to anti-EGFR antibodies, KRAS G13-mutant organoids demonstrated sensitivity comparable to that of KRAS wild-type organoids. Transcriptomic analysis of a KRAS G13-mutant organoid after anti-EGFR antibody treatment revealed significant alterations in gene expression, with enrichment of MYC-related signaling pathways. These results were supported by in silico analyses using public cancer cell line datasets, which showed relatively lower IC50 values for KRAS G13-mutant cells than for KRAS G12-mutant cells. Moreover, anti-EGFR antibody treatment induced the expression of apoptosis-related genes in KRAS G13-mutant organoids, and pharmacological inhibition of MYC signaling attenuated drug sensitivity, indicating a functional role for MYC activation in mediating therapeutic response. Altogether, our results demonstrate heterogeneity in anti-EGFR antibody sensitivity among KRAS-mutant CRCs and identify KRAS G13-mutant tumors as a subset with preserved responsiveness. These data provide mechanistic insights into subtype-specific differences in therapeutic vulnerability and suggest that downstream transcriptional programs, including MYC signaling, contribute to sensitivity to EGFR-targeted therapy.

2026-05-14 | GSE330032 | GEO

The E3 ubiquitin ligase HUWE1 is required for KRAS-induced lung cancer

Project description:The E3 ubiquitin ligase HUWE1 modifies a diverse network of substrate proteins by ubiquitination, through which it regulates various intracellular processes and contributes to both oncogenic and tumour suppressor mechanisms in different cancer contexts. Here, by analysing human lung adenocarcinoma (LUAD) patient samples, we reveal that HUWE1 protein expression is commonly upregulated in LUAD tumours compared to normal adjacent lung tissue and that this increase is associated with tumour stage. Using multiple, independent murine models of LUAD initiation and growth, we identify that Huwe1 is essential for mutant Kras-induced lung tumour development and reveal a novel, p53-independent requirement for Huwe1 in LUAD. Mechanistically, we demonstrate induction of senescence following HUWE1 depletion - characterised by impaired proliferation, an atypical cell cycle distribution, emergence of morphologically abnormal enlarged cells, increased β-galactosidase activity, and transcriptional reprogramming associated with inflammatory senescence-associated secretory phenotype (SASP) signalling and NFκB activation. Together, these data highlight a crucial role for HUWE1 in mutant Kras-induced LUAD tumorigenesis and in the continued growth and proliferation of established LUAD cells, confirming HUWE1 as a rational therapeutic target for LUAD.

2026-02-27 | GSE290690 | GEO

Targeted KRAS G12V degradation elicits efficient and durable lung adenocarcinoma regression in vivo [dTAG_expt3_RNAseq]

Project description:Recent drug discovery breakthroughs led to the approval of KRASG12C inhibitors in lung adenocarcinoma (LUAD). Unfortunately, clinical responses are often hampered by the rapid emergence of resistance. Proteolysis-targeting chimeras (PROTACs) have emerged as promising alternatives to traditional inhibition. However, there is limited mechanistic understanding of KRAS degradation in vivo. Here, we developed a preclinical LUAD mouse model and demonstrated that targeted oncogenic KRAS degradation induces rapid tumor regression primarily due to cancer cell-intrinsic mechanisms. Yet, transcriptional, histological, and immunophenotypic analyses revealed a substantial remodeling of the tumor microenvironment. Notably, disease relapse observed during prolongued degrader treatment stems from proteolysis machinery dysregulation, indicating resistance mechanisms distinct from those reported upon KRAS inhibition. Collectively, our findings highlight the therapeutic potential of KRAS degradation in LUAD, providing insights into both cell-intrinsic and -extrinsic mechanisms that accompany antitumor responses and support the continued clinical development of this approach.

2026-05-14 | GSE326057 | GEO

Targeted KRAS G12V degradation elicits efficient and durable lung adenocarcinoma regression in vivo [R_invivo_invitro]

2026-05-14 | GSE301620 | GEO

Targeted KRAS G12V degradation elicits efficient and durable lung adenocarcinoma regression in vivo [dTAG_expt2_RNAseq]

2026-05-14 | GSE301302 | GEO

Targeted KRAS G12V degradation elicits efficient and durable lung adenocarcinoma regression in vivo [dTAG_expt1_RNAseq]

2026-05-14 | GSE301301 | GEO